Acute Myeloid Leukemia |
From the Medizinische Klinik II, Abt. Hämatologie/Onkologie, Klinikum der Johann Wolfgang Goethe-Universität Frankfurt, Frankfurt, Germany (GB, KS, MK, DH, OGO, MR); MLL Münchner Leukämielabor GmbH, München, Germany (CS); Institut für Transfusionsmedizin und Immunhämatologie, DRK-Blutspendedienst Baden-Württemberg - Hessen GmbH, Frankfurt, Germany (RH).
Correspondence: Gesine Bug, Medizinische Klinik II, Abt. Hämatologie/Onkologie, Klinikum der Johann Wolfgang Goethe-Universität Frankfurt, Theodor-Stern-Kai 7, 60590 Frankfurt, Germany. Email: g.bug{at}em.uni-frankfurt.de
Histone deacetylase inhibitor valproic acid (VPA) was recently shown to enhance proliferation and self-renewal of normal hematopoietic stem cells, raising the possibility that VPA may also support growth of leukemic progenitor cells (LPC). Here, VPA maintains a significantly higher proportion of CD34+ LPC and colony forming units compared to control cultures in six AML samples, but selectively reduces leukemic cell numbers in another AML sample with expression of AML1/ETO. Our data suggest a differential effect of VPA on the small population of AML progenitor cells and the bulk of aberrantly differentiated blasts in the majority of AML samples tested.
Key words: histone deacetylase inhibitor, CD34+ leukemic progenitor cells, interphase FISH, AML1/ETO, AML blast colonies.
This article has been cited by other articles:
![]() |
K. Schmidt, K. Seeger, C. Scheibenbogen, R. Bender, M. Abdulla, S. Sussmilch, A. Salama, and A. Moldenhauer Histone deacetylase inhibition improves differentiation of dendritic cells from leukemic blasts of patients with TEL/AML1-positive acute lymphoblastic leukemia J. Leukoc. Biol., March 1, 2009; 85(3): 563 - 573. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Haferlach Molecular Genetic Pathways as Therapeutic Targets in Acute Myeloid Leukemia Hematology, January 1, 2008; 2008(1): 400 - 411. [Abstract] [Full Text] [PDF] |
||||